As mentioned in my previous message, SNY’s expectation of “further erosion” in Lovenox share is only from the fact that 3Q10 was a partial quarter for the generic competitor. On the CC, it was clear that SNY intends to keep its market share close to where it is now, give or take a few percentage points.
Market Data 
Markets 
AI
